Medication info
Tripm Duo Tablet 2.5/500 mg (Linagliptin, Metformin)

Tripm Duo Tablet 2.5/500 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Yellow, oval, film-coated tablets with a double convex shape
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401055 · Approved 2024.04.30 · Insurance code 622805280

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each ingredient: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Inadequate blood glucose control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medication, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes improve blood sugar control while following dietary and exercise regimens. It is used to effectively manage blood sugar levels through the combination of linagliptin and metformin.

How to take

Adult dose

The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each ingredient: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Inadequate blood glucose control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medication, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).

Precautions

This medication helps to control blood sugar levels. However, there is a risk of serious side effects such as lactic acidosis, which can occur rarely, thus caution is necessary. Individuals who are allergic to any of the components of this product, have type 1 diabetes, lactic acidosis, or severe renal impairment should not use this medication. Additionally, it should not be taken by individuals who are dehydrated, have severe infections, heart failure, liver dysfunction, acute alcohol intoxication, or pregnant or breastfeeding women. Since there is a risk of hypoglycemia, blood sugar levels should be monitored frequently and doses adjusted as needed when used with insulin or sulfonylureas. In cases of decreased renal function, the use of this medication is limited, and regular kidney function tests should be conducted. Acute pancreatitis or skin blistering disorders may occur, so if severe abdominal pain or skin abnormalities persist while taking this medication, immediate consultation with a doctor is necessary. Common side effects include gastrointestinal disorders, especially diarrhea, abdominal pain, decreased appetite, and vomiting, which typically improve over time. Vitamin B12 deficiency may occur, so it is recommended to check vitamin B12 levels through blood tests during prolonged use. If pregnant or planning to become pregnant, this medication should be avoided, and other treatment options should be discussed as necessary. Safety for use in children or adolescents has not been established, and it is not recommended for children under 10 years old. Elderly patients often experience decreased kidney function, so dosage adjustments and regular kidney function monitoring are necessary. There is insufficient research on the effects of this medication on driving or operating machinery, so caution is advised. In case of overdose, there is a risk of lactic acidosis; immediate medical treatment is required, and, if necessary, the removal of the drug can be done via hemodialysis. This medication should be stored in a tightly sealed container to prevent exposure to moisture and direct sunlight, and kept out of reach of children.

Side effects

Lactic acidosis, hypoglycemia, taste disturbance, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function test, hepatitis, pruritus, erythema, rash, bullous pemphigoid, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, increased triglycerides in the blood, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, increased ALT, increased triglycerides in the blood, flushing, itching, anxiety, mood disorders, insomnia, depression, cerebral infarction, speech impairment, Alzheimer's dementia, cerebral infarction, diabetic neuropathy, headache, sensory disturbances, postherpetic neuralgia, partial paralysis, syncope, drowsiness, fatigue, chest discomfort, weakness, death, pain, nasal bleeding, oropharyngeal pain, chronic obstructive pulmonary disease, voice disorder, allergic rhinitis, exertional dyspnea, wet cough, asthma, rhinorrhea, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, male pattern baldness, diabetic foot, hyperhidrosis, hair loss, skin lesions, dermatitis, anxiety, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, pneumonia, rhinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, epigastric pain, rectal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, dizziness, inadequate control of diabetes, malnutrition, hyponatremia, dehydration, increased creatinine in the blood, facial edema, hyperthermia, back pain, palpitations, contusion, bone contusion, concussion, bone fracture, hand fracture, pneumoconiosis, laceration, dry eye, cataract, ocular discomfort, allergic conjunctivitis, hearing loss, erectile dysfunction, goiter, kidney transplant failure, anemia, nocturia, dermatitis, confusional state, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain the storage temperature between 1 to 30 degrees Celsius at room temperature. This will help ensure the medication's effectiveness is preserved and remains safe for a long time.

Appearance and packaging

Appearance

Yellow, oval, film-coated tablets with a double convex shape

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.